Our approaches are listed in Table 1.
CS 1.
Final numbers of the recruitment are presented in Table 2.
See Deliverables 2.4 and 2.5.
CS 2.
Final numbers of recruitment are presented in Table 3.
See Deliverables 1.4 and 3.3.
CS 3A.
Final numbers of recruitment are presented in Figure 1.
See Deliverable 4.5.
CS 3B.
Final numbers of recruitment are presented in Table 4.
See Deliverable 2.6.
Almost 95 % of achievements on recruitment, reached the study expectations of recruitment, and allowed us to proceed with the analysis and integration of the results.
During this period, the sample characterization and analysis were performed, and publications are under preparation. One abstract was accepted at ESMO World GI Congress in July 2023, and two abstracts were accepted and will be presented at the poster session at ESMO, Madrid in October 2023.
Summary of the clinical study conclusions.
- Legacy clinical study 1: Significant differences were found regarding lifestyles, diet, and clinical characteristics comparing patients and controls, and comparing EU and LATAM regions. Deliverables 2.4 and 2.5.
- Legacy clinical study 2: After a deep analysis of the LECACy samples, integrating clinical, pathological, and molecular data, we can conclude that gastric cancer subtypes with the highest clinical and biological value are based on validated markers (HER2, MSI/dMMR and EBV) in addition to histopathology (intestinal or diffuse). Regional differences were found in the clinical, pathological, immune, and molecular characteristics. Deliverables 1.4 and 3.3.
- Legacy clinical study 3, Part A: Educational Intervention. The results showed that the intervention improved the knowledge of GC risk factors and symptoms for a short period, but after 3 months, the participants forgot it. Deliverable 4.5.
Therefore, we propose the performance of recurring campaigns focused on gastric cancer awareness, to ensure a higher rate of alphabetization regarding gastric cancer risks and symptoms.
- Legacy clinical study 3, Part B: H. pylori Registry. Overall, we see that quadruple therapies (both, with and without bismuth) are superior to OCA treatment for H. Pylori eradication in the overall recruited cohort, belonging to five different countries and two continents, in line with previously published data. We consider this type of study useful to show which are better treatment options and let the clinical sites of the consortia to adapt to these tested therapeutic approaches. Deliverable 2.6.
The LEGACy clinical studies met the specific endpoints providing new data with a holistic overview of gastric cancer epidemiological, clinical, protein, molecular, immune, and microbiome characteristics of EU and CELAC cohorts, which have been presented to the scientific community and the civic population through different channels. Moreover, our interventional study showed positive results, as a strategy for gastric cancer prevention, that could be easily applied worldwide.
The educational program, including the training and knowledge exchange of the protocols that will be applied for each GC sample, performed during this reporting period:
- Six online educational sessions on relevant topics in GC (17 during the overall project), including international experts lecturing these sessions. The fellowship program is still ongoing.
- At least one exchange session per sub-WP after the first batch of samples was analyzed at the different laboratories.
Finally, the dissemination activities have been carried out in accordance with the project communication plan. During this period the main objective has been raising awareness of the project and preparing the future dissemination and exploitation of the results.
